Skip to content

Treatment of uremic restless legs syndrom with stellate ganglion block

Treatment of uremic restless legs syndrom with stellate ganglion block

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076719
Enrollment
Unknown
Registered
2023-10-17
Start date
2022-03-15
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Restless legs syndrome

Interventions

Sponsors

Shanxi Bethune Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) aged between 20 and 80 years old 2) chronic renal failure with regular dialysis for at least 3 months 3) meet the diagnostic criteria of restless legs syndrome, with IRLS score =15 4) Informed consent was obtained voluntarily

Exclusion criteria

Exclusion criteria: 1) severe impairment of cardiopulmonary function, abnormal coagulation function, puncture site infection or severe systemic infection. 2) various mental or neurological diseases, other sleep disorders. 3) Prosthetic vascular access in the leg region. 4) peripheral neuropathy and vascular problems in the lower extremities. 5) history of other movement disorders such as Parkinson's disease, dyskinesia, and dystonia. 6) Inability to cooperate, communication disorder (language disorder, severe visual or hearing impairment). 7) Being pregnant or breastfeeding. 8) are participating in other clinical investigators.

Design outcomes

Primary

MeasureTime frame
Polysomnography;International Restless Legs Scale (IRLS);RLS Quality of Life Questionnaire (RLS-QOL);Pittsburgh Sleep Quality Index (PSQI);

Secondary

MeasureTime frame
Parathyroid hormone (PTH);C-reactive protein (CRP);Blood pressure variability (BVP);Interleukin-1ß (IL-1ß);Heart rate variability (HRV);

Countries

China

Contacts

Public ContactWeiwei Zhang

Shanxi Bethune Hospital

sxbqeyyzww@163.com+86 152 3412 1313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026